

## Evaluation of *GJB2* and *GJB6* Mutations in Patients Afflicted with Non-syndromic Hearing Loss

Seyed Hamid Reza Abtahi<sup>1</sup>, Ali Malekzadeh<sup>2</sup>, Saeed Soheilipour<sup>3</sup>, Mansoor Salehi<sup>4</sup>, Roya Taleban<sup>5</sup>, Reyhaneh Rabieian<sup>6</sup>, \*Mohammad Moafi<sup>7</sup>

<sup>1</sup>Associate Professor of Otolaryngology, Department of Otolaryngology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. <sup>2</sup>Resident of Otolaryngology, Department of Otolaryngology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. <sup>3</sup>Professor of Otolaryngology, Department of Otolaryngology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. <sup>4</sup>Professor of Medical Genetic, Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. <sup>5</sup>Community Medicine Specialist, Acquired Immunodeficiency Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. <sup>6</sup>MSc. in Medical Genetic, Department of Genetics and Molecular Biology, Isfahan University of Medical Sciences, Isfahan, Iran. <sup>7</sup>Postdoctoral Research Fellow, Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-communicable Diseases, Isfahan University of Medical Sciences, Isfahan, Iran.

### Abstract

#### Background

Non-syndromic hearing loss (NSHL) is assumed as one of the highly prevalent congenital defects in the world. In this regard, *gap junction protein beta 2* (*GJB2*), and *gap junction protein beta 6* (*GJB6*) mutations are considered as the leading congenital causes of deafness. The present study aimed to assess the prevalence of *GJB2* and *GJB6* mutations in NSHL cases.

#### Materials and Methods

This cross-sectional study was implemented from Jan. 2015 to Sep. 2017 at Alzahra Hospital (Isfahan, Iran). 46 patients afflicted with NSHL were recognized and recruited by physicians. Heparinized blood was collected and DNA of each participant was extracted. Genetic analysis of *GJB2* and *GJB6* genes was performed using PCR and GAP-PCR methods respectively.

**Results:** 35delG mutation had the highest prevalence with allelic frequency of 6.12%. The allelic frequencies of 35delG, and delE120 were 6(6.12%), and 3(3.06%), respectively. Allelic frequency of W77R, Y65H, G160, and R127H was 2(2.04%) for each of them. In addition, 2 patients were heterozygous for p.V153I rare polymorphism (2.04%).

#### Conclusion

Overall, the present study indicated that 35delG mutation could be considered as the foremost causative factor of NHCL. *GJB2* mutations were highly prevalent among NSHL cases (23.9%). As a result, the mutation analysis of this gene could be appropriately used for prevention and early diagnosis of NSHL.

**Key Words:** Hearing Loss, *GJB2*, *GJB6*, Mutation.

\*Please cite this article as: Abtahi SHR, Malekzadeh A, Soheilipour S, Salehi M, Taleban R, Rabieian R, et al. Evaluation of *GJB2* and *GJB6* Mutations in Patients Afflicted with Non-syndromic Hearing Loss. *Int J Pediatr* 2019; 7(2): 9053-60. DOI: **10.22038/ijp.2018.34154.3017**

#### \*Corresponding Author:

Mohammad Moafi (Ph.D), Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-communicable Diseases, Isfahan University of Medical Sciences, Isfahan, Iran.

Email: mohammoafi@yahoo.com

Received date: Jul.27, 2018; Accepted date: Oct. 22, 2018

## 1- INTRODUCTION

Hearing loss is one of the most prevalent forms of the sensorineural and congenital defects (1, 2). World Health Organization (WHO) states that about 360 million individuals around the world, have been afflicted with mild to severe hearing loss (3). This impairment impedes speech progression, causing many social and vocational implications (2). Hearing loss is a heterogeneous disorder since it could be induced by both environmental factors and genetic defects (2). The role of the genetic factors, however, surpasses the others (3). The non-syndromic hearing loss (NSHL) may be induced by 150 loci mutations and it could have autosomal recessive (80%), autosomal dominant (10%), X-linked (<1%), Y-linked (<1%), and mitochondrial (<1%) basis. Most of the genetic defects are induced by DFNB1 locus mutation (MIM#220290), including two genes: *gap junction protein beta 2 (GJB2)*, and *gap junction protein beta 6 (GJB6)* (1-5).

*GJB2* (MIM 121011, GeneID 2706) comprises two exons, one of which can be translated. This gene encodes connexin-26 protein (26 kDa), constructed from 226 amino acids (4-6). This protein has a four-transmembrane spanning structure and is expressed in hair cells (5, 7). Connexin-26 is involved in potassium recycling of endolymph fluid; hence, *GJB2* mutations impede K<sup>+</sup> recycling and lead to necrosis of hair cells (5, 8). Moreover, connexin 26 expression is crucial for cochlear development (5, 9). In fact, abnormal *GJB2* causes cochlear amplification impairment, endolymphatic potential reduction, and hair cell degeneration (5, 10). Some forms of hearing loss, however, are caused by monoallelic mutations of *GJB2* accompanied with a second mutation of *GJB6* (MIM 604418, GeneID 10804) (11, 12). This gene encodes a protein, called connexin-30(30kDa), comprised of 261 amino acids (11, 13).

Connexin 30 constitutes gap junction between the hair cells (11, 14). The gap junction, also known hemiconnexon structure, allows the transmission of ions and some metabolites (11, 15). The first and conformational structures of connexin 30 and 26 closely resemble each other (11, 16). Moreover, these proteins are expressed simultaneously (11, 15). There is no question that consanguinity is a risk factor of autosomal recessive hearing loss in different populations (5). Besides, previous studies have reported high levels of hearing loss (3 in 1000 newborns) and consanguinity (36.8%) in Iran (2, 4, 5). The current study aimed to assess *GJB2* and *GJB6* mutations in NSHL cases living in Isfahan, a metropolis in the center of Iran.

## 2- MATERIALS AND METHODS

### 2-1. Study design and population

This was a cross-sectional study carried out at Alzahra Hospital (Isfahan University of Medical Sciences (IUMS), Isfahan, Iran from Jan. 2015 to Sept. 2017. Sample size was estimated according to the previous studies (n=46)(17, 18).

### 2-2. Ethical considerations

This study was approved by the Ethical Committee of IUMS (Project Code: 395819). All parts of the study protocol and its aims were clearly described for the patients and their guardians, and informed consent was acquired. The participants were assured that their information would be kept confidential.

### 2-3. Inclusion and exclusion criteria

The inclusion criteria for patient recruitment were: (1) participants afflicted by moderate (40-70 decibel (dB)), severe (70-95 dB), or profound (>95 dB) NSHL, (2) patients having autosomal recessive hearing loss. Exclusion criteria were deafness caused by: (1) conductive hearing loss, (2) toxic drugs used during the

pregnancy, (3) septicemia and related antibiotic therapies in neonates, (4) trauma and other environmental factors.

#### 2-4. Laboratory assessment

Heparinized peripheral blood (5 ml) was collected from every patient and DNA was extracted, using a DNA extraction kit (Qiagen, Germany Cat. No 51304) according to the manufacturer's instructions. DNA concentration and quality were assessed by determination of 260A/280A using a NonoDrop spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) and agarose gel (2%) electrophoresis.

The coding exon of *GJB2* gene was amplified by PCR method. For DNA amplification the forward (CTCCCTGTTCTGTCTAGCT) and reverse (CTCATCCCTCTCATGCTGTC) primers (Cox26E2) that were applied yielded 809 bp band (19). Standard PCR was done in a solution comprised of 40 ng genomic DNA (1.5µl), 100 pml of each primer (0.2µl), 10mM deoxyribonucleotide triphosphates (dNTP) (0.5µl), 50mM MgCl<sub>2</sub> (1µl), 10 X PCR buffer (2.5µl), 5 U/ml Taq polymerase(0.2µl) in a final volume of 25µl. PCR amplification conditions were: denaturation at 94 °C for 4 min, followed by 30 cycles of denaturation at 94 °C for 1 min, annealing at 61°C for 1 min, extension at 72 °C for 90 s, and finally 5 min at 72 °C. All of the amplicons were purified through Wizard SV Gel and PCR clean-up system (Promega).

*GJB6* gene was assessed by Multiplex PCR assay. DNA amplification was carried out through three primers: Cox 30: forward, AGGGATAAACCAGCGCAATG, reverse, AGCACAACCTCTGCCACGTTA (20); Gjb6: forward, TTTAGGGCATGATTGGGGTGATTT, reverse, CACCATGCGTAGCCTTAACCATTTT

(19); Actin: CGGAACCGCTCATTGCC, reverse, ACCCACACTGTGCCCATCTA (21). The reaction was carried out in 25µl total volume for each sample, including 40 ng genomic DNA (1.5µl), 100 pml of each primer (0.2µl), 10mM deoxyribonucleotide triphosphates (dNTP) (0.5µl), 50mM MgCl<sub>2</sub> (1µl), 10 X PCR buffer (2.5µl), 5 U/ml Taq polymerase(0.2µl). This multiplex PCR condition was set up as follows: denaturation at 94 °C for 4 min, followed by 30 cycles of denaturation at 94 °C for 1 min, annealing at 62 °C for 1 min, extension at 72 °C for 1 min, and finally 7 min at 72 °C.

#### 2-5. Data Analyses

The Sanger sequencing was carried out on an ABI 3130 automated sequencer (XL genetic analyser) using the BigDye terminator V.3.1. All of the results were aligned with human *GJB2* sequences presented in Human Genome Database and GenBank. The common deletions of *GJB6* were assessed through GAP-PCR method.

#### 2-6. Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

### 3- RESULTS


In this study, 46 unrelated patients (30 males and 16 females) aged from 2 to 36 years were analyzed (**Table.1**). All of them were from consanguineous marriage (mostly first cousins), and 89% of the patients had a history of hearing loss in their family members (more than one affected patient in a pedigree). Partial or total hearing loss in all of them was not associated with other signs and symptoms. Coding exon of *GJB2* was amplified and sequenced with specific primers.

Sequencing results revealed that 2 patients had homozygote 35delG mutation and one of them had heterozygote 35delG. c.229 T>C (p.Trp77Arg) and c.195C>A (p.Tyr65His) mutations were found in homozygote status. Two patients had c.358-360delGAG (p.Glu120del) mutation (one homozygote and one heterozygote). c.478G>A (p.Gly160Ser) and p.R127H mutations were found in heterozygote forms in 2 separate patients. The allelic frequencies of 35delG, and del E120 were 6(6.12%) and 3(3.06%) respectively.

Allelic frequency of W77R, Y65H, G160 and R127H was 2(2.04%) for each of them. In addition, 2 patients were heterozygous for p.V153I rare polymorphism (2.04%) (**Figure.1**). Clinical data, family characterization and genotype of patients bearing specific *GJB2* variants are listed in **Table.2**. D13S1830 deletion of *GJB6* gene was also analyzed by multiplex gap PCR and as was expected no deletion was shown in our 46 deaf patients.

**Table-1:** Baseline characteristic of the patients afflicted by non-syndromic hearing loss

Patient's Characteristic	Statistics
Age, year mean (range)	13 (2-36)
Gender: Number (%) Male	30 (65.21)
Nationality: Number (%) Iranian	46 (100)
History of hearing loss in family members	41 (89)
Level of consanguinity	46 (100)



**Fig.1:** Mutation found in gap junction protein beta 2(*GJB2*) gene.

**Table-2:** The clinical data and family history of deaf patients bearing specific *GJB2* variants

No.	Gender	Age at diagnosis	Hearing loss severity	Consanguinity of parents	Family history	Identified mutation
1	F	At birth	Sever	No	+	35delG/N rs398123814
2	M	At birth	Sever	No	-	c.478G>A (p.Gly160Ser)/N rs34988750
3	M	At birth	Profound	Yes	+	35delG/35delG rs398123814
4	F	4 years	Sever	Yes	+	c.195C>A (p.Tyr65His) / c.195C>A (p.Tyr65His) rs763572195
5	M	2 years	Moderate	Yes	+	c.358-360 delGAG (p.Glu120del) / c.358-360 delGAG (p.Glu120del) rs150529554
6	F	At birth	Profound	No	+	c.229T>C (p.Trp77Arg)/ c.229T>C (p.Trp77Arg) rs104894397
7	M	At birth	Sever	Yes	+	c.380G>T(R127H)/N rs111033196
8	F	7 years	Profound	Yes	-	c.457G>A(V153I)/N rs111033186
9	M	At birth	Sever	Yes	+	c.358-360 delGAG (p.Glu120del) /N rs150529554
10	F	At birth	Sever	No	-	c.457G>A(V153I)/N rs111033186
11	M	At birth	Profound	No	+	35delG/35delG rs398123814

F: female; M: male.

#### 4- DISCUSSION

In the present study, 16 varied alleles were detected in 11 of 46 patients. In this regard, 35delG mutation had the highest prevalence with allelic frequency of 6.12%. Our findings were in agreement with the previous studies conducted in other provinces of Iran, which reported high prevalence of 35delG mutation (12%) (22-27). Genetic screening of *GJB2* gene could be assumed as the first step for molecular analysis of patients afflicted by NSHL. According to the Human Gene Mutation Database (HGMD®) (<http://www.hgmd.cf.ac.uk>), more than 200 variants in the *GJB2* gene have been reported. Among these, variants deletion of guanine in position 30-35 (named 35del G) is the most frequent mutation (roughly 70%) of *GJB2* variants (28). The other prevalent mutations of *GJB2* found in Iran are R127H, delE120, W24X, R184P, -

3170G>A (IVSI-1G>A) and 235delC (29-31). D13S1830 deletion in *GJB6* gene has been considered as not only the most frequent deletion but also the second frequent mutation in white populations (32). Del Castillo et al found that more than half of patients with heterozygote variants in *GJB2* gene have a large deletion in that gene (33). The D13S1830 deletion is the most frequent deletion of *GJB6* in France (33, 34), Spain (33), Brazil (35), Argentina (36), and UK (33). This deletion removes 309 Kb near *GJB6* and *GJB2* and terminates *GJB6* (13). It is still unclear whether mutations in *GJB2* gene can be inherited in digenic pattern with D13S1830 deletion or whether the removed region contains common regulatory elements of *GJB2* and *GJB6* genes (37-39). The frequency of *GJB6* deletion varies wildly among different populations (40). This deletion was absent

in the current study and not reported in Turkey (41), India (42) and China (43). The delE120 (deletion of glutamic acid in codon120 mutation) was the other mutation detected in the current study, and found in 3.06% of alleles (44, 45). This deletion is also reported as the second prevalent mutation in some western, and southwestern parts of Iran (18, 45, 46). Pathogenicity of R127H variant which leads to substitution of arginine for histidine is not confirmed and is controversial among different mutation prediction software. Another common polymorphism in *GJB2* gene is V153I, substitution of Valine for Isoleucine due to G to A transition. Since gene polymorphisms could change sequence of coding protein, association of these polymorphisms with other polymorphisms in this gene or another gene may result in some degree of hearing loss. Previous studies showed that variable phenotypic manifestation of mutations, may be due to association of modifier agents (18, 47). In this study, we identified patients with homozygote *GJB2* mutations. The patients who have heterozygote *GJB2* mutations and *GJB2* negative patients were subjected to further clinical and molecular analysis. However, none of the cases were affected by *GJB6* mutation. Our findings supported previous results, indicating the absence of *GJB6* mutation in Iranian population (48).

#### 4-1. Limitations of the study

There are unknown genetic mutation contributing to NSH, as a result, expanded genetic screening of NSHL cases could be beneficial.

#### 5- CONCLUSION

The results showed that distraction technique had a good effect on the intensity of pain in children. Given the need for pain control and its effects on the course of treatment, further studies are needed to be done.

#### 6- ACKNOWLEDGMENT

We would like to thank the vice chancellor for research at Isfahan University of Medical Sciences (IUMS) for the financial support. This study was funded by IUMS (grant number: 395819).

#### 7- CONFLICT OF INTEREST: None.

#### 8- REFERENCES

1. Hasanpour M TM, Aein F, Yadegarfar G. The effects of two non-pharmacologic pain management methods for intramuscular injection pain in children. *Acute pain* 2006; 8(1):7-12.
2. Kaheni S, Rezai MS, Bagheri-Nesami M, Goudarzian AH. The Effect of Distraction Technique on the Pain of Dressing Change in 3-6 Year-old Children. *International Journal of Pediatrics* 2016; 4(4):1603-10.
3. Groß M, Warschburger P. Evaluation of a cognitive-behavioral pain management program for children with chronic abdominal pain: a randomized controlled study. *Int J Behav Med* 2013; 20(3):434-43.
4. Turk D MR. Hand book of pain assessment. 2 ed: New York: Guilford Press; 2001.
5. American academy of pediatrics. Committee on psychosocial aspects of Child and family Health. Task force on pain in infants Children and adolescents a. The assessment and management of acute pain in infants, children and adolescents. *Pediatric* 2001; 108(3):793-7.
6. Wong DL HM, Wilson D, Winkelstein ML, Kline NE. Wong's nursing care of infants and children. 7th ed: Louis: Mosby; 2003.
7. C VHV. Nurses' perceptions of children's pain: a pilot study of cognitive representations. *J Pain Symptom Manage* 2007; 33(3):290-301.
8. Alavi A ZA, Abdi Yazdan Z, Nam Nabati M. The comparison of distraction and EMLA cream effects on pain intensity due to intravenous catheters in 5-12 years old

Thalassemic children. *Shahrekord University of Medical Sciences Journal* 2005; 7(3):15-9.

9. Genik LM, McMurtry CM, Breau LM. Observer perceptions of pain in children with cognitive impairments: vignette development and validation. *Pain Manag* 2015; 5(6):425-34.

10. Spacek A. Modern concepts of acute and chronic pain management. *Biomed Pharmacother* 2006; 60(4):329-35.

11. M P. Effect of oral glucose solution on some physiological and behavioral indices of pain due to blood sampling in hospitalized neonates in Rasht hospital: Nursing Faculty of Guilan University of Medical Sciences; 2006.

12. Lee EK, Yeo Y. Relaxation practice for health in the United States: findings from the National Health Interview Survey. *J Holist Nurs* 2013; 31(2):139-48.

13. A G. Primary health care of infants. Children and adolescents: New York: Mosby; 2002.

14. Alavi A ZA, Abde Yazdan Z, Namnabat M. Study of distraction and Emla cream on the pain intensity catheter insertion in children with thalassemic age 5- 8 years old. *Shahrekord Uni Med Sci J* 2005; 7(3):9-15.

15. Uman LS CC, McGrath PJ, Kisely S. Psychological interventions for needle-related procedural pain and distress in children and adolescents. *Cochrane Database Syst Rev* 2006; 18(4):CD005179.

16. Migdal M C-PE, Vause E, Henry E, Lazar J. Rapid, needle-free delivery of lidocaine for reducing the pain of venipuncture among pediatric subjects. *Pediatric* 2005; 115(4):393-8.

17. Wang ZX SL, Chen AP. The efficacy of non-pharmacological methods of pain management in school-age children receiving venipuncture in a paediatric department: a randomized controlled trial of audiovisual distraction and routine psychological intervention. *Swiss Med Wkly* 2008; 138(39-40):579-84.

18. Bagheri-Nesami M, Mohseni-Bandpei MA, Shayesteh-Azar M. The effect of Benson relaxation technique on rheumatoid arthritis patients. *Int J Nurs Pract* 2006; 12: 214-19.

19. Masoumeh Bagheri-Nesam, Fatemeh Espahbodi, Attieh Nikkha, Seyed Afshin Shorofi, Jamshid Yazdani Charati. The effects of lavender aromatherapy on pain following needle insertion into a fistula in hemodialysis patients. *Complement Ther Clin Pract* 2014; 20(1):1-4.

20. Heidari Gorji MA, Bagheri Nesami M, Ayyasi M, Ghafari R, Yazdani J. Comparison of Ice Packs Application and Relaxation Therapy in Pain Reduction during Chest Tube Removal Following Cardiac Surgery. *N Am J Med Sci* 2014; 6(1):19-24.

21. Masoumeh Bagheri Nesami, Nahid ZargaR, Afshin Gholipour Baradari The Effect of Foot Reflexology Massage on Pain and Fatigue of Patients undergoing Coronary Artery Bypass Graft. *Journal of Mazandaran University of Medical Sciences* 2012; 22(92):51-62.

22. Alavi A, Namnabat M, Abde Yazdan Z, Parvin N, Akbari N, Samipour V, et al. Pediatric pain management by nurses in educational hospitals of Shahrekord in 2006. *Shahrekord University of Medical Sciences Journal* 2008; 10(2):66-71. [Persian]

23. Yoo H KS, Hur HK, Kim HS. The effects of an animation distraction intervention on pain response of preschool children during venipuncture. *Appl Nurs Res* 2011; 24(2):94-100.

24. Gupta D ea. An evaluation of efficacy of balloon inflation on venous cannulation pain in children: a prospective, randomized, controlled study. *Anesth Analg* 2006; 102(5):1372-5.

25. Press J GY, Maimon M, Gonen A, Goldman V, Buskila D. Effects of active distraction on pain of children undergoing venipuncture: Who benefits from it? *The Pain Clinic* 2003; 15(3):261-9.

26. LL C. Comparative study of distraction versus topical anesthesia for pediatric pain management during immunizations. *Health Psychol* 1999; 18(6):591.

27. Fowler-Kerry S, Lander JR. Management of injection pain in children. *Pain* 1987; 30(2):169-75.

28. Thrane SE, Wanless S, Cohen SM, Danford CA. The Assessment and Non-Pharmacologic Treatment of Procedural Pain from Infancy to School Age through a Developmental Lens: A Synthesis of Evidence with Recommendations. *J Pediatr Nurs* 2016; 31(1):23-32.
29. Kleiber C, McCarthy AM. Evaluating instruments for a study on children's responses to a painful procedure when parents are distraction coaches. *J Pediatr Nurs* 2006; 21(2):99-107.
30. Pellino TA, Gordon DB, Engelke ZK, Busse KL, Collins MA, Silver CE, Norcross NJ. Use of nonpharmacologic interventions for pain and anxiety after total hip and total knee arthroplasty. *Orthop Nurs* 2005; 24(3):182-90.
31. Association GAotWM. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. *J Am Coll Dent* 2014; 81(3):14.
32. Diette GB, Lechtzin N, Haponik E, Devrotes A, Rubin HR. Distraction therapy with nature sights and sounds reduces pain during flexible bronchoscopy: a complementary approach to routine analgesia. *Chest* 2003; 123(3):941-8.
33. Rice BA, Nelson C. Safety in the pediatric ICU: the key to quality outcomes. *Crit Care Nurs Clin North Am* 2005; 17(4):431-40.
34. Kuttner L, Bowman M, Teasdale M. Psychological treatment of distress, pain, and anxiety for young children with cancer. *J Dev Behav Pediatr* 1988; 9(6):374-81.
35. Vosoghi N, Chehrzad M, Abotalebi G, Atrkar Roshan Z. Effects of Distraction on Physiologic Indices and Pain Intensity in children aged 3-6 Undergoing IV Injection. *HAYAT* 2011; 16 (3 and 4):39-47. [Persian]
36. Chiang LC, Ma WF, Huang JL, Tseng LF, Hsueh KC. Effect of relaxation-breathing training on anxiety and asthma signs/symptoms of children with moderate-to-severe asthma: a randomized controlled trial. *Int J Nurs Stud* 2009; 46(8):1061-70.
37. Kleiber C, Harper DC. Effects of distraction on children's pain and distress during medical procedures: a meta-analysis. *Nurs Res* 1999; 48(1):44-9.
38. Landolt MA, Marti D, Widmer J, Meuli M. Does cartoon movie distraction decrease burned children's pain behavior? *J Burn Care Rehabil* 2002; 23(1):61-5.
39. Windich-Biermeier A, Sjoberg I, Dale JC, Eshelman D, Guzzetta CE. Effects of distraction on pain, fear, and distress during venous port access and venipuncture in children and adolescents with cancer. *J Pediatr Oncol Nurs*. 2007; 24(1):8-19.
40. Wang ZX, Sun LH, Chen AP. The efficacy of non-pharmacological methods of pain management in school age children receiving venipuncture in a pediatric department: A randomized controlled trial of audiovisual distraction and routine psychological intervention. *Swiss Med Wkly* 2008; 138(39-40):579-84.
41. Blount RL, Zempsky WT, Jaaniste T, Evans S, Cohen LL, Devine KA, et al. Management of pediatric pain and distress due to medical procedures. In M.C. Roberts & R.G. Steele (Eds.), *Handbook of Pediatric Psychology*. New York: Guilford Press; 2009.